Geron Corp. (GERN) and GE Healthcare, a unit of General Electric Co. (GE), announced Tuesday morning that they entered into a global exclusive license and alliance agreement to develop and commercialize cellular assay products derived from human embryonic stem cells for use in drug discovery, development and toxicity screening.
Geron Corp. gapped up sharply Tuesday, but was range-bound for the majority of the session. Shares closed higher by $0.98 at $7.67 on the highest volume in 5 months. The stock finished at a 4 1/2 month high.
For comments and feedback: editorial@rttnews.com